{"id":139,"date":"2026-03-29T02:04:44","date_gmt":"2026-03-29T02:04:44","guid":{"rendered":"https:\/\/edmpackz.com\/?p=139"},"modified":"2026-03-29T02:04:44","modified_gmt":"2026-03-29T02:04:44","slug":"vesiculobullous-eruption-with-loncastuximab-tesirine-in-a-patient-with-relapsed-follicular-lymphoma","status":"publish","type":"post","link":"https:\/\/edmpackz.com\/?p=139","title":{"rendered":"Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma"},"content":{"rendered":"<div class=\"LicenseInfo text-xs u-margin-xs-bottom\">\n<div class=\"AccessLabel\"><\/div>\n<\/div>\n<section class=\"ReferencedArticles\"><\/section>\n<section class=\"ReferencedArticles\"><\/section>\n<div class=\"PageDivider\"><\/div>\n<ul id=\"issue-navigation\" class=\"issue-navigation u-margin-s-bottom u-bg-grey1\">\n<li class=\"previous move-left u-padding-s-ver u-padding-s-left\"><a class=\"button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-left\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624002820\"><span class=\"button-alternative-text-container\"><span class=\"button-alternative-text\">Previous\u00a0<span class=\"extra-detail-1\">article<\/span><span class=\"extra-detail-2\">\u00a0in issue<\/span><\/span><\/span><\/a><\/li>\n<li class=\"next move-right u-padding-s-ver u-padding-s-right\"><a class=\"button-alternative button-alternative-tertiary u-display-flex button-alternative-icon-right\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003278\"><span class=\"button-alternative-text-container\"><span class=\"button-alternative-text\">Next\u00a0<span class=\"extra-detail-1\">article<\/span><span class=\"extra-detail-2\">\u00a0in issue<\/span><\/span><\/span><\/a><\/li>\n<\/ul>\n<div class=\"Keywords u-font-serif\">\n<div id=\"kwrds0010\" class=\"keywords-section\" lang=\"en\">\n<h2 class=\"section-title u-h4 u-margin-l-top u-margin-xs-bottom\">Key words<\/h2>\n<div id=\"kwrd0010\" class=\"keyword\">dermatologic toxicity<\/div>\n<div id=\"kwrd0015\" class=\"keyword\">follicular lymphoma<\/div>\n<div id=\"kwrd0020\" class=\"keyword\">interface dermatitis<\/div>\n<div id=\"kwrd0025\" class=\"keyword\">loncastuximab tesirine<\/div>\n<div id=\"kwrd0030\" class=\"keyword\">oncologic dermatology<\/div>\n<div id=\"kwrd0035\" class=\"keyword\">vesiculobullous dermatitis<\/div>\n<\/div>\n<div id=\"kwrds0015\" class=\"keywords-section\" lang=\"en\">\n<h2 class=\"section-title u-h4 u-margin-l-top u-margin-xs-bottom\">Abbreviations used<\/h2>\n<div id=\"kwrd0040\" class=\"keyword\">ADC<\/p>\n<div id=\"kwrd0045\" class=\"keyword\">antibody-drug complex<\/div>\n<\/div>\n<div id=\"kwrd0050\" class=\"keyword\">CD<\/p>\n<div id=\"kwrd0055\" class=\"keyword\">cluster of differentiation<\/div>\n<\/div>\n<div id=\"kwrd0060\" class=\"keyword\">LT<\/p>\n<div id=\"kwrd0065\" class=\"keyword\">loncastuximab tesirine<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div id=\"body\" class=\"Body u-font-serif\">\n<div>\n<section id=\"sec1\">\n<h2 id=\"sectitle0020\" class=\"u-h4 u-margin-l-top u-margin-xs-bottom\">Introduction<\/h2>\n<div id=\"p0010\" class=\"u-margin-s-bottom\"><a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/loncastuximab-tesirine\">Loncastuximab tesirine<\/a>\u00a0(LT) is an antibody-drug conjugate (ADC) that has shown efficacy in patients with relapsed\/refractory B-cell\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/cancer\">malignancies<\/a>.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib1\" name=\"bbib1\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>1<\/sup><\/span><\/span><\/a><sup>,<\/sup><a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib2\" name=\"bbib2\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>2<\/sup><\/span><\/span><\/a>\u00a0It comprises an anti-cluster of differentiation (CD)19 antibody linked to the pyrrolobenzodiazepine dimer SG3199, a potent inter-strand minor-groove\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/dna-cross-linking\">DNA crosslinking<\/a>\u00a0agent, and has prolonged cytotoxic activity against CD19<sup>+<\/sup>\u00a0cells.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib3\" name=\"bbib3\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>3<\/sup><\/span><\/span><\/a>\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/skin-toxicity\">Cutaneous toxicities<\/a>\u00a0to LT are limited due to its specificity and short half-life, with reactions including a nonspecific maculopapular or pustular rash,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/photosensitivity\">photosensitivity<\/a>, and ulcers.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib4\" name=\"bbib4\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>4<\/sup><\/span><\/span><\/a>\u00a0Two cases of a photodistributed eruption and subsequent\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/vesicular-rash\">vesicular lesions<\/a>\u00a0and edema have been reported with LT.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib5\" name=\"bbib5\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>5<\/sup><\/span><\/span><\/a>\u00a0Here, we report a third case of blistering lesions associated with LT, with similar clinical and histopathological findings, in a patient with relapsed\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/follicular-lymphoma\">follicular lymphoma<\/a>. Our case expands on the initial series in corroborating salient features of this eruption and in reporting the results of therapeutic intervention and a timeline to resolution.<\/div>\n<\/section>\n<section id=\"sec2\">\n<h2 id=\"sectitle0025\" class=\"u-h4 u-margin-l-top u-margin-xs-bottom\">Case presentation<\/h2>\n<div id=\"p0015\" class=\"u-margin-s-bottom\">The patient is a 55-year-old man with a history of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/follicular-lymphoma\">follicular lymphoma<\/a>\u00a0first diagnosed in 2014. He was started on\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/rituximab\">rituximab<\/a>\u00a0with 2\u00a0years of maintenance therapy and experienced a good partial response. He developed progressive\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/lymphadenopathy\">lymphadenopathy<\/a>\u00a0in late 2019 that progressed despite additional rituximab and trials of 8 cycles of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/obinutuzumab\">obinutuzumab<\/a>\u00a0(anti-CD20), 6 cycles of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/bendamustine\">bendamustine<\/a>, and a 5-month trial of the EZH2 inhibitor\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/tazemetostat\">tazemetostat<\/a>.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib6\" name=\"bbib6\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib6\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>6<\/sup><\/span><\/span><\/a>\u00a0Repeat\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/lymph-node-biopsy\">lymph node biopsy<\/a>\u00a0showed loss of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/cd20\">CD20<\/a>\u00a0expression. At this point, he was enrolled in the LOTIS-7\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/clinical-trial\">clinical trial<\/a>\u00a0of the anti-CD19 antibody loncastuximab teserine with the anti-CD79\u00a0B antibody\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/polatuzumab-vedotin\">polatuzumab vedotin<\/a>,<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib7\" name=\"bbib7\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib7\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>7<\/sup><\/span><\/span><\/a>\u00a0with his first treatment in March 2023.<\/div>\n<div class=\"u-margin-s-bottom\">\n<div id=\"p0020\">During the third cycle of treatment, the patient developed a nonpruritic rash on the head and neck that progressed to include redness and swelling of both hands (<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#fig1\" name=\"bfig1\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"fig1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Fig 1<\/span><\/span><\/a>,\u00a0<em>A<\/em>) and the feeling of a \u201csunburn.\u201d A\u00a0week later, he reported worsening with a \u201cburning\u201d sensation, mild pruritus, swollen hands, and sloughing of the skin. He was referred to our clinic, where physical exam showed confluent red, slightly poikilodermatous, thin plaques with dusky\/gray exfoliative scale in a photo-distributed pattern and a solitary, 1\u00a0millimeter tense vesicle on the right ulnar wrist (<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#fig1\" name=\"bfig1\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"fig1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Fig 1<\/span><\/span><\/a>,\u00a0<em>B<\/em>\u00a0and\u00a0<em>C<\/em>). He reported regular\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/sunscreen\">sunscreen<\/a>\u00a0application and worked at night without significant sun exposure. Biopsy of the wrist lesion showed intraepidermal vesiculation and interface vacuolar dermatitis in the context of a mixed lymphohistiocytic infiltrate (<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#fig2\" name=\"bfig2\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"fig2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Fig 2<\/span><\/span><\/a>), with the direct\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/immunofluorescence\">immunofluorescence<\/a>\u00a0finding of granular C3 and rare dot-like IgA deposition along the\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/basement-membrane-zone\">basement membrane zone<\/a>. PAS and herpes simplex virus\/varicella zoster virus immunostains were negative. Given these findings, a vesiculobullous reaction to loncastuximab was favored over other considerations: herpes simplex virus\/varicella zoster virus and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/dermatophyte\">dermatophytes<\/a>\u00a0were not detected; histology and immunofluorescence were not characteristic of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/bullous-pemphigoid\">bullous pemphigoid<\/a>,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/porphyria-cutanea-tarda\">porphyria cutanea tarda<\/a>, or\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/connective-tissue-disease\">connective tissue disease<\/a>\u00a0(in particular, intraepidermal vesiculation is uncharacteristic of connective tissue diseases). The clinical appearance was considered less typical of dyshidrotic dermatitis or\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/skin-allergy\">allergic contact dermatitis<\/a>. Twice daily\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/clobetasol\">clobetasol<\/a>\u00a00.05% ointment to the hands and continued strict sun protection were recommended.<\/div>\n<figure id=\"fig1\" class=\"figure text-xs\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr1.jpg\" alt=\"\" height=\"244\" aria-describedby=\"cap0010\" \/><\/p>\n<ol class=\"u-margin-s-bottom\">\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download high-res image (744KB)\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr1_lrg.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download high-res image (744KB)<\/span><\/span><\/span><\/a><\/li>\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download full-size image\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr1.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download full-size image<\/span><\/span><\/span><\/a><\/li>\n<\/ol>\n<p id=\"fspara0010\"><span class=\"label\">Fig 1<\/span>.\u00a0Initial presentation of the patient\u2019s lesions.\u00a0<strong>A,<\/strong>\u00a0Diffuse erythema and swelling of bilateral hands.\u00a0<strong>B,<\/strong>\u00a0<em>Red<\/em>, poikilodermatous plaques with dusky scale in a photodistribution on the neck.\u00a0<strong>C,<\/strong>\u00a0Tense vesicle on the right ulnar wrist. Histopathology findings of the biopsied lesion are shown in\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#fig2\" name=\"bfig2\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"fig2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Fig 2<\/span><\/span><\/a>.<\/p>\n<\/figure>\n<figure id=\"fig2\" class=\"figure text-xs\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr2.jpg\" alt=\"\" height=\"237\" aria-describedby=\"cap0015\" \/><\/p>\n<ol class=\"u-margin-s-bottom\">\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download high-res image (1015KB)\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr2_lrg.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download high-res image (1015KB)<\/span><\/span><\/span><\/a><\/li>\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download full-size image\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr2.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download full-size image<\/span><\/span><\/span><\/a><\/li>\n<\/ol>\n<p id=\"fspara0015\"><span class=\"label\">Fig 2<\/span>.\u00a0Histopathology of the vesicle on the right ulnar wrist.\u00a0<strong>A,<\/strong>\u00a0Intraepidermal vesiculation with necrosis and exocytosis of lymphocytes, histiocytes, neutrophils, and eosinophils. Hematoxylin and eosin, original magnification \u00d740.\u00a0<strong>B,<\/strong>\u00a0Interface dermatitis with basal vacuolization and dyskeratosis, lymphohistiocytic infiltrate, and basket-weave orthokeratosis. Hematoxylin and eosin, original magnification \u00d740.<\/p>\n<\/figure>\n<\/div>\n<div class=\"u-margin-s-bottom\">\n<div id=\"p0025\">At follow-up 6\u00a0weeks later (4\u00a0weeks after his last infusion), his rash had spread beyond his head\/neck and upper extremities, and he reported lower extremity edema, blisters, and a painful\/burning sensation with occasional itch. Exam showed numerous semi-tense vesicles on a bright pink to red\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/base\">base<\/a>\u00a0on the dorsal feet and ankles, dusky firm edematous plaques with epidermal peeling in bilateral popliteal fossae, and superficial abrasion\/ulceration on the right calf from minimal\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/injury\">trauma<\/a>\u00a0(<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#fig3\" name=\"bfig3\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"fig3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Fig 3<\/span><\/span><\/a>). The loncastuximab and polatuzumab were held, and he was removed from the\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/clinical-trial\">clinical trial<\/a>\u00a0due to progression of the\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/skin-defect\">skin lesions<\/a>\u00a0and worsening\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/transaminase\">transaminase<\/a>\u00a0elevation. He was started on a 1-week\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/prednisone\">prednisone<\/a>\u00a0taper starting at 0.5\u00a0mg\/kg (40\u00a0mg) daily. Within 4\u00a0days of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/prednisone\">prednisone<\/a>\u00a0initiation, his rash and edema had improved, and they were completely resolved at 3-month follow-up.<\/div>\n<figure id=\"fig3\" class=\"figure text-xs\"><img decoding=\"async\" src=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr3.jpg\" alt=\"\" height=\"377\" aria-describedby=\"cap0020\" \/><\/p>\n<ol class=\"u-margin-s-bottom\">\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download high-res image (830KB)\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr3_lrg.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download high-res image (830KB)<\/span><\/span><\/span><\/a><\/li>\n<li><a class=\"anchor download-link u-font-sans anchor-primary\" title=\"Download full-size image\" href=\"https:\/\/ars.els-cdn.com\/content\/image\/1-s2.0-S2352512624003291-gr3.jpg\" target=\"_blank\" rel=\"noopener\" download=\"\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Download:\u00a0<span class=\"download-link-title\">Download full-size image<\/span><\/span><\/span><\/a><\/li>\n<\/ol>\n<p id=\"fspara0020\"><span class=\"label\">Fig 3<\/span>.\u00a0Progression of vesiculobullous eruption.\u00a0<strong>A,<\/strong>\u00a0Diffuse erythema with semi-tense vesicles on the dorsal feet and ankles.\u00a0<strong>B,<\/strong>\u00a0Dusky\u00a0<em>purple<\/em>\u00a0plaques with scale in the bilateral popliteal fossae, with erosions on the right calf from minimal trauma.<\/p>\n<\/figure>\n<\/div>\n<\/section>\n<section id=\"sec3\">\n<h2 id=\"sectitle0030\" class=\"u-h4 u-margin-l-top u-margin-xs-bottom\">Discussion<\/h2>\n<div class=\"u-margin-s-bottom\">\n<div id=\"p0030\">Vesiculobullous reactions are exceedingly rare with\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/monoclonal-antibody-therapy\">monoclonal antibody therapy<\/a>\u00a0for\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/hematologic-malignancy\">hematologic malignancies<\/a>, with isolated cases of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/bullous-dermatitis\">bullous dermatitis<\/a>\u00a0and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/epidermolysis-bullosa-acquisita\">epidermolysis bullosa acquisita<\/a>\u00a0reported with\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/rituximab\">rituximab<\/a>.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib4\" name=\"bbib4\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>4<\/sup><\/span><\/span><\/a>\u00a0Here, we report a third case of a blistering\/vesicular eruption with unique clinical and histopathologic findings in a B-cell lymphoma patient receiving\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/loncastuximab-tesirine\">LT<\/a>\u00a0(<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#tbl1\" name=\"btbl1\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"tbl1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Table I<\/span><\/span><\/a>). Pruritus,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/photosensitivity\">photosensitivity<\/a>,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/morbilliform\">morbilliform<\/a>\u00a0or\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/papulopustular\">papulopustular<\/a>\u00a0eruptions, and lower extremity edema have previously been reported with LT.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib4\" name=\"bbib4\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>4<\/sup><\/span><\/span><\/a><sup>,<\/sup><a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib8\" name=\"bbib8\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib8\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>8<\/sup><\/span><\/span><\/a>\u00a0Bullous lesions with vesicular\/interface dermatitis,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/epileptic-absence\">absence<\/a>\u00a0of dermal edema, and focal\/granular deposition of IgA along the\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/basement-membrane\">basement membrane<\/a>\u00a0have not been reported except in one previous report.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib5\" name=\"bbib5\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>5<\/sup><\/span><\/span><\/a>\u00a0As previously noted, the vesicular lesions had a unique presentation and pathology distinguishing them from bullous eruptions associated with\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/peripheral-edema\">peripheral edema<\/a>\u00a0and toxic erythema of chemotherapy. Both patients in the previous report received LT\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/monotherapy\">monotherapy<\/a>, while our patient also received\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/polatuzumab-vedotin\">polatuzumab vedotin<\/a>. However,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/skin-manifestation\">cutaneous reactions<\/a>\u00a0with this agent are rare and overlap with other ADCs containing monomethyl auristatin e as their cytotoxic payload, and bullous eruptions with this agent have not been reported. Although bullous reactions to the Nectin-4-targeted\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/antibody-drug-conjugate\">ADC<\/a>\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/enfortumab-vedotin\">enfortumab vedotin<\/a>\u00a0(which also contains monomethyl auristatin e) have been reported, these are thought to be secondary to the targeting of Nectin-4, which is involved in cell-cell adhesion in the epidermis.<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib4\" name=\"bbib4\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>4<\/sup><\/span><\/span><\/a><\/div>\n<div id=\"tbl1\" class=\"tables frame-topbot colsep-0 rowsep-0\">\n<p id=\"tspara0010\"><span class=\"label\">Table I<\/span>.\u00a0Patient demographic characteristics, oncologic history, dermatological clinical and pathologic features, management, and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/disease-course\">clinical course<\/a><\/p>\n<div class=\"groups\">\n<table>\n<thead>\n<tr class=\"rowsep-1 valign-top\">\n<td scope=\"col\"><span class=\"screen-reader-only\">Empty Cell<\/span><\/td>\n<th scope=\"col\">Case 1<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib5\" name=\"bbib5\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>5<\/sup><\/span><\/span><\/a><\/th>\n<th scope=\"col\">Case 2<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib5\" name=\"bbib5\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>5<\/sup><\/span><\/span><\/a><\/th>\n<th scope=\"col\">Our case<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr class=\"valign-top\">\n<th scope=\"row\">Age\/gender<\/th>\n<td>98\/F<\/td>\n<td>68\/M<\/td>\n<td>55\/M<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Diagnosis<\/th>\n<td>MZL \u2192 DLBCL<\/td>\n<td>FL \u2192 DLBCL<\/td>\n<td>Relapsed FL<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Previous treatment<\/th>\n<td>R-CHOP, BR, ibrutinib<\/td>\n<td>R-CHOP, R-GemOx, radiation<\/td>\n<td>Rituximab, obinutuzumab, bendamustine, tazemetostat<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Treatment at time of reaction<\/th>\n<td>LT monotherapy<\/td>\n<td>LT monotherapy<\/td>\n<td>LT and polatuzumab vedotin<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Time to onset of vesicular rash<\/th>\n<td>3 cycles (7\u00a0weeks)<\/td>\n<td>4 cycles (12\u00a0weeks)<\/td>\n<td>3 cycles (8\u00a0weeks)<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Other skin manifestations<\/th>\n<td>Preceding photodistributed rash involving other sites; new-onset bilateral lower extremity edema<\/td>\n<td>Preceding photodistributed rash involving other sites; worsening of existing bilateral lower extremity edema<\/td>\n<td>Preceding photodistributed nonpruritic rash on head\/neck spreading caudally; new-onset lower extremity edema<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Biopsy H&amp;E<\/th>\n<td>Subepidermal vesicular dermatitis, no dermal edema<\/td>\n<td>Subepidermal vesicular dermatitis, interface dermatitis, no dermal edema<\/td>\n<td>Vesiculobullous dermatitis, interface dermatitis, no dermal edema<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Biopsy DIF<\/th>\n<td>Fine granular IgA at basement membrane<\/td>\n<td>Fine grains of IgA alone basement membrane zone<\/td>\n<td>Focal dot-like\/granular IgA along basement membrane zone<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Management<\/th>\n<td>Supportive<\/td>\n<td>Supportive<\/td>\n<td>Topical clobetasol, prednisone 0.5 mg\/kg \u00d7 1 wk<\/td>\n<\/tr>\n<tr class=\"valign-top\">\n<th scope=\"row\">Treatment status\/outcome<\/th>\n<td>Discontinued with resolution of symptoms, no recurrence<\/td>\n<td>Discontinued, patient deceased<\/td>\n<td>Discontinued with improvement in symptoms, no recurrence<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"legend\">\n<div id=\"tspara0015\" class=\"u-margin-s-bottom\"><em>BR<\/em>, Bendamustine and rituximab;\u00a0<em>DIF<\/em>, direct\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/immunofluorescence\">immunofluorescence<\/a>;\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/diffuse-large-b-cell-lymphoma\">DLBCL<\/a>, diffuse large B-cell lymphoma;\u00a0<em>F<\/em>, female;\u00a0<em>FL<\/em>, follicular lymphoma;\u00a0<em>H&amp;E<\/em>,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/haematoxylin\">hematoxylin<\/a>\u00a0and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/eosin\">eosin<\/a>;\u00a0<em>LT<\/em>, loncastuzimab\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/tesirine\">tesirine<\/a>;\u00a0<em>M<\/em>, male;\u00a0<em>MZL<\/em>,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/malt-lymphoma\">marginal zone lymphoma<\/a>;\u00a0<em>R-CHOP<\/em>, rituximab,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/cyclophosphamide\">cyclophosphamide<\/a>, hydroxydaunorubicin (doxorubicin),\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/vincristine-sulfate\">oncovin<\/a>\u00a0(vincristine), and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/prednisolone\">prednisolone<\/a>;\u00a0<em>R-GemOx<\/em>, rituximab,\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/gemcitabine\">gemcitabine<\/a>, and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/oxaliplatin\">oxaliplatin<\/a>.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div id=\"p0035\" class=\"u-margin-s-bottom\">All patients in the previous report received supportive treatment, and LT was discontinued, although not specifically due to the cutaneous eruption. Our patient\u2019s rash was one of two concomitant toxicities contributing to the discontinuation of LT, the other being\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/transaminase\">transaminase<\/a>\u00a0elevations to 5 times the upper limit of normal. His eruption did improve with topical\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/clobetasol\">clobetasol<\/a>\u00a0and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/prednisone\">prednisone<\/a>, although his LT had been discontinued by the time of initiation of\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/prednisone\">prednisone<\/a>, and it is unclear which of these was responsible for his improvement.<\/div>\n<div id=\"p0040\" class=\"u-margin-s-bottom\">In summary, this case contributes to the very limited body of literature on the\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/skin-toxicity\">cutaneous toxicities<\/a>\u00a0associated with LT and provides other dermatologists with the results of our therapeutic intervention. Reported\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/pharmacology-toxicology-and-pharmaceutical-science\/adverse-event\">adverse reactions<\/a>\u00a0to other tesirine-containing ADCs include morbilliform\/acneiform eruptions, pruritus, and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/photosensitivity\">photosensitivity<\/a>\u00a0with camidanlumab\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/tesirine\">tesirine<\/a>\u00a0(anti-CD25)<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib9\" name=\"bbib9\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib9\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>9<\/sup><\/span><\/span><\/a>\u00a0and\u00a0<a class=\"topic-link\" href=\"https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/rovalpituzumab-tesirine\">rovalpituzumab tesirine<\/a>\u00a0(anti-delta-like protein 3).<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib10\" name=\"bbib10\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>10<\/sup><\/span><\/span><\/a>\u00a0Isolated cases of dose-limited \u201cbullous dermatitis\u201d have been reported with rovalpituzumab tesirine,<a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bib10\" name=\"bbib10\" data-sd-ui-side-panel-opener=\"true\" data-xocs-content-type=\"reference\" data-xocs-content-id=\"bib10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><sup>10<\/sup><\/span><\/span><\/a>\u00a0although the reactions were not described. Further study is needed to elucidate the mechanism of this and similar eruptions.<\/div>\n<\/section>\n<\/div>\n<section id=\"coi0010\">\n<h2 id=\"sectitle0035\" class=\"u-h4 u-margin-l-top u-margin-xs-bottom\">Conflicts of interest<\/h2>\n<div id=\"p0045\" class=\"u-margin-s-bottom\">Dr Hornick reports a relationship with Shook Hardy &amp; Bacon LLP that includes consulting or advisory. Drs Seervai, Okada, and Mengden-Koon have no conflicts of interest to declare.<\/div>\n<\/section>\n<\/div>\n<div class=\"Tail\"><\/div>\n<div>\n<section id=\"cebib0010\" class=\"bibliography u-font-serif text-s\">\n<h2 class=\"section-title u-h4 u-margin-l-top u-margin-xs-bottom\">References<\/h2>\n<section id=\"cebibsec0010\" class=\"bibliography-sec\">\n<ol id=\"reference-links-cebibsec0010\" class=\"references\">\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib1\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib1\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">1<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">B.S.\u00a0Kahl,\u00a0M.\u00a0Hamadani,\u00a0J.\u00a0Radford,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref1\" class=\"title text-m\">A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody\u2013drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Clin Cancer Res,\u00a025\u00a0(2019), pp.\u00a06986-6994,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0711\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1158\/1078-0432.CCR-19-0711<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85075960499&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=A%20phase%20I%20study%20of%20ADCT-402%20%2C%20a%20novel%20pyrrolobenzodiazepine-based%20antibodydrug%20conjugate%2C%20in%20relapsedrefractory%20B-cell%20non-Hodgkin%20lymphoma&amp;publication_year=2019&amp;author=B.S.%20Kahl&amp;author=M.%20Hamadani&amp;author=J.%20Radford\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref1\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib2\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib2\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">2<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">P.F.\u00a0Caimi,\u00a0W.\u00a0Ai,\u00a0J.P.\u00a0Alderuccio,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref2\" class=\"title text-m\">Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Lancet Oncol,\u00a022\u00a0(2021), pp.\u00a0790-800,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(21)00139-X\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1016\/S1470-2045(21)00139-X<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S147020452100139X\/pdfft?md5=79c12ba2531de3a55c4cd4e2cfc8606d&amp;pid=1-s2.0-S147020452100139X-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S147020452100139X\" aria-describedby=\"ref-id-sref2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85107129023&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Loncastuximab%20tesirine%20in%20relapsed%20or%20refractory%20diffuse%20large%20B-cell%20lymphoma%20%3A%20a%20multicentre%2C%20open-label%2C%20single-arm%2C%20phase%202%20trial&amp;publication_year=2021&amp;author=P.F.%20Caimi&amp;author=W.%20Ai&amp;author=J.P.%20Alderuccio\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref2\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib3\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib3\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">3<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">E.\u00a0Calabretta,\u00a0M.\u00a0Hamadani,\u00a0P.L.\u00a0Zinzani,\u00a0P.\u00a0Caimi,\u00a0C.\u00a0Carlo-Stella<\/div>\n<div id=\"ref-id-sref3\" class=\"title text-m\">The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Blood,\u00a0140\u00a0(2022), pp.\u00a0303-308,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1182\/blood.2021014663\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1182\/blood.2021014663<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497122006693\/pdfft?md5=7246feb336e7545fe34dc189e521f130&amp;pid=1-s2.0-S0006497122006693-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497122006693\" aria-describedby=\"ref-id-sref3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85135069541&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=The%20antibody-drug%20conjugate%20loncastuximab%20tesirine%20for%20the%20treatment%20of%20diffuse%20large%20B-cell%20lymphoma&amp;publication_year=2022&amp;author=E.%20Calabretta&amp;author=M.%20Hamadani&amp;author=P.L.%20Zinzani&amp;author=P.%20Caimi&amp;author=C.%20Carlo-Stella\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref3\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib4\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib4\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">4<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">R.N.H.\u00a0Seervai,\u00a0S.K.\u00a0Friske,\u00a0E.Y.\u00a0Chu,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref4\" class=\"title text-m\">The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy<\/div>\n<\/div>\n<div class=\"host u-font-sans\">J Cutan Pathol,\u00a050\u00a0(2023), pp.\u00a072-95,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1111\/cup.14327\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1111\/cup.14327<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85139196201&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=The%20diverse%20landscape%20of%20dermatologic%20toxicities%20of%20non-immune%20checkpoint%20inhibitor%20monoclonal%20antibody-based%20cancer%20therapy&amp;publication_year=2023&amp;author=R.N.H.%20Seervai&amp;author=S.K.%20Friske&amp;author=E.Y.%20Chu\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref4\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib5\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib5\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">5<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">S.\u00a0Gociman,\u00a0K.\u00a0Baron,\u00a0B.\u00a0Hu,\u00a0J.\u00a0Zussman,\u00a0L.M.\u00a0Madigan<\/div>\n<div id=\"ref-id-sref5\" class=\"title text-m\">Blistering lesions associated with loncastuximab tesirine<\/div>\n<\/div>\n<div class=\"host u-font-sans\">JAMA Dermatol,\u00a0158\u00a0(2022), pp.\u00a0831-832,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1389\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1001\/jamadermatol.2022.1389<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85131156778&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Blistering%20lesions%20associated%20with%20loncastuximab%20tesirine&amp;publication_year=2022&amp;author=S.%20Gociman&amp;author=K.%20Baron&amp;author=B.%20Hu&amp;author=J.%20Zussman&amp;author=L.M.%20Madigan\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref5\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib6\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib6\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">6<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">F.\u00a0Morschhauser,\u00a0H.\u00a0Tilly,\u00a0A.\u00a0Chaidos,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref6\" class=\"title text-m\">Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Lancet Oncol,\u00a021\u00a0(2020), pp.\u00a01433-1442,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1016\/s1470-2045(20)30441-1\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1016\/s1470-2045(20)30441-1<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204520304411\/pdfft?md5=5a6b00f64f8caf4aae137c56598fb6c9&amp;pid=1-s2.0-S1470204520304411-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref6\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204520304411\" aria-describedby=\"ref-id-sref6\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85094819055&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref6\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Tazemetostat%20for%20patients%20with%20relapsed%20or%20refractory%20follicular%20lymphoma%3A%20an%20open-label%2C%20single-arm%2C%20multicentre%2C%20phase%202%20trial&amp;publication_year=2020&amp;author=F.%20Morschhauser&amp;author=H.%20Tilly&amp;author=A.%20Chaidos\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref6\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib7\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib7\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">7<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">B.T.\u00a0Hess,\u00a0M.M.\u00a0Solh,\u00a0M.\u00a0Gandhi,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref7\" class=\"title text-m\">Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (LOTIS-7)<\/div>\n<\/div>\n<div class=\"host u-font-sans\">J Clin Oncol,\u00a041\u00a0(2023), Article\u00a0TPS7581,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS7581\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1200\/JCO.2023.41.16_suppl.TPS7581<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Phase%201b%20open-label%20study%20of%20loncastuximab%20tesirine%20in%20combination%20with%20other%20anticancer%20agents%20in%20patients%20with%20relapsedrefractory%20B-cell%20non-Hodgkin%20lymphoma%20&amp;publication_year=2023&amp;author=B.T.%20Hess&amp;author=M.M.%20Solh&amp;author=M.%20Gandhi\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref7\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib8\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib8\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">8<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">J.P.\u00a0Alderuccio,\u00a0K.\u00a0Ardeshna,\u00a0B.\u00a0Hess,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref8\" class=\"title text-m\">Incidence, onset, and management of edema and effusion in patients treated with loncastuximab tesirine for R\/R DLBCL in the LOTIS clinical trial program<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Clin Lymphoma Myeloma Leuk,\u00a021\u00a0(2021), pp.\u00a0S397-S398<\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2152265021018991\/pdfft?md5=52d17bd8acf3c3a82d6087874bce737d&amp;pid=1-s2.0-S2152265021018991-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref8\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2152265021018991\" aria-describedby=\"ref-id-sref8\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Incidence%2C%20onset%2C%20and%20management%20of%20edema%20and%20effusion%20in%20patients%20treated%20with%20loncastuximab%20tesirine%20for%20RR%20DLBCL%20in%20the%20LOTIS%20clinical%20trial%20program&amp;publication_year=2021&amp;author=J.P.%20Alderuccio&amp;author=K.%20Ardeshna&amp;author=B.%20Hess\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref8\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib9\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib9\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">9<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">M.\u00a0Hamadani,\u00a0G.P.\u00a0Collins,\u00a0P.F.\u00a0Caimi,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref9\" class=\"title text-m\">Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Lancet Haematol,\u00a08\u00a0(2021), pp.\u00a0e433-e445,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1016\/s2352-3026(21)00103-4\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1016\/s2352-3026(21)00103-4<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352302621001034\/pdfft?md5=70171f33ead87b739375fd7f4a87bcf7&amp;pid=1-s2.0-S2352302621001034-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref9\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352302621001034\" aria-describedby=\"ref-id-sref9\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85106530441&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref9\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Camidanlumab%20tesirine%20in%20patients%20with%20relapsed%20or%20refractory%20lymphoma%3A%20a%20phase%201%2C%20open-label%2C%20multicentre%2C%20dose-escalation%2C%20dose-expansion%20study&amp;publication_year=2021&amp;author=M.%20Hamadani&amp;author=G.P.%20Collins&amp;author=P.F.%20Caimi\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref9\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<li><span class=\"label u-font-sans\"><a id=\"ref-id-bib10\" class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352512624003291#bbib10\" data-aa-button=\"sd:product:journal:article:location=references:type=anchor:name=citation-name\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10<\/span><\/span><\/a><\/span>\n<div class=\"contribution\">\n<div class=\"authors u-font-sans\">C.M.\u00a0Rudin,\u00a0M.C.\u00a0Pietanza,\u00a0T.M.\u00a0Bauer,\u00a0<em>et al.<\/em><\/div>\n<div id=\"ref-id-sref10\" class=\"title text-m\">Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study<\/div>\n<\/div>\n<div class=\"host u-font-sans\">Lancet Oncol,\u00a018\u00a0(2017), pp.\u00a042-51,\u00a0<a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1016\/s1470-2045(16)30565-4\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">10.1016\/s1470-2045(16)30565-4<\/span><\/span><\/a><\/div>\n<div class=\"ReferenceLinks u-font-sans\" lang=\"en\" data-aa-region=\"reference-links\"><a class=\"anchor pdf link anchor-primary anchor-icon-left anchor-with-icon\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204516305654\/pdfft?md5=4defb8cb3c7299adc6eac2746d2ee283&amp;pid=1-s2.0-S1470204516305654-main.pdf\" target=\"_blank\" rel=\"nofollow noopener\" aria-describedby=\"ref-id-sref10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View PDF<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204516305654\" aria-describedby=\"ref-id-sref10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View article<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-85007506761&amp;partnerID=10&amp;rel=R3.0.0\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">View in Scopus<\/span><\/span><\/a><a class=\"anchor link anchor-primary\" href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Rovalpituzumab%20tesirine%2C%20a%20DLL3-targeted%20antibody-drug%20conjugate%2C%20in%20recurrent%20small-cell%20lung%20cancer%3A%20a%20first-in-human%2C%20first-in-class%2C%20open-label%2C%20phase%201%20study&amp;publication_year=2017&amp;author=C.M.%20Rudin&amp;author=M.C.%20Pietanza&amp;author=T.M.%20Bauer\" target=\"_blank\" rel=\"noopener noreferrer\" aria-describedby=\"ref-id-sref10\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Google Scholar<\/span><\/span><\/a><\/div>\n<\/li>\n<\/ol>\n<\/section>\n<\/section>\n<\/div>\n<div id=\"section-cited-by\">\n<section class=\"ListArticles preview\" aria-label=\"Cited by\">\n<div class=\"PageDivider\"><\/div>\n<header id=\"citing-articles-header\">\n<h2 class=\"u-h4 u-margin-l-ver u-font-serif\">Cited by (2)<\/h2>\n<\/header>\n<div aria-describedby=\"citing-articles-header\">\n<div class=\"citing-articles u-margin-l-bottom\">\n<ul>\n<li class=\"ListArticleItem u-margin-l-bottom\">\n<div class=\"sub-heading u-margin-xs-bottom\">\n<h3 id=\"citing-articles-article-0-title\" class=\"u-font-serif\"><a class=\"anchor anchor-primary\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962226002793\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Dermatologic adverse events associated with antibody-drug conjugate loncastuximab: A retrospective multicenter cohort study<\/span><\/span><\/a><\/h3>\n<div>2026, Journal of the American Academy of Dermatology<\/div>\n<\/div>\n<div class=\"buttons\"><\/div>\n<\/li>\n<li class=\"ListArticleItem u-margin-l-bottom\">\n<div class=\"sub-heading u-margin-xs-bottom\">\n<h3 id=\"citing-articles-article-1-title\" class=\"u-font-serif\"><a class=\"anchor anchor-primary\" href=\"https:\/\/doi.org\/10.1002\/hon.70128\" target=\"_blank\" rel=\"noopener\"><span class=\"anchor-text-container\"><span class=\"anchor-text\">Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma<\/span><\/span><\/a><\/h3>\n<div>2025, Hematological Oncology<\/div>\n<\/div>\n<div class=\"buttons\"><\/div>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<div class=\"Footnotes text-xs\">\n<dl class=\"footnote\">\n<dt class=\"footnote-label\"><\/dt>\n<dd class=\"footnote-detail u-padding-xs-top\">\n<div id=\"ntpara0010\" class=\"u-margin-s-bottom\">Funding sources: None.<\/div>\n<\/dd>\n<\/dl>\n<dl class=\"footnote\">\n<dt class=\"footnote-label\"><\/dt>\n<dd class=\"footnote-detail u-padding-xs-top\">\n<div id=\"ntpara0015\" class=\"u-margin-s-bottom\">Patient consent: The authors obtained written consent from the patient for their photographs and medical information to be published in print and online, with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors.<\/div>\n<\/dd>\n<\/dl>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Previous\u00a0article\u00a0in issue Next\u00a0article\u00a0in issue Key words dermatologic toxicity follicular lymphoma interface dermatitis loncastuximab tesirine oncologic dermatology vesiculobullous dermatitis Abbreviations used ADC antibody-drug complex CD cluster of differentiation LT loncastuximab tesirine &hellip; <\/p>\n","protected":false},"author":1,"featured_media":140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=139"}],"version-history":[{"count":1,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/139\/revisions"}],"predecessor-version":[{"id":141,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/posts\/139\/revisions\/141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=\/wp\/v2\/media\/140"}],"wp:attachment":[{"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/edmpackz.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}